Skip to main content

The rise and fall of metastatic clones under immune attack

Project description

Immune system versus metastatic cancer cells

One of the hallmarks of cancer is metastasis: the ability of cancer cells to escape the primary tumour, migrate and colonise distant sites. Significant evidence over the years has highlighted the process, yet little is known about how these cells escape immune recognition. The EU-funded EVOMET project is focusing on colorectal cancer, which has a very low survival rate once metastatic. Researchers are working under the hypothesis that metastatic cancer cells escape immune surveillance through the suppression of neoantigens. Being able to quantify the relation between the immune system and tumour cells will pave the way for novel anti-cancer interventions. 

Coordinator

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Net EU contribution
€ 224 933,76
Address
Old Brompton Road 123
SW7 3RP London
United Kingdom

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00